Common Genetic Determinants of Intraocular Pressure and Primary Open-Angle Glaucoma

Grants

Funding Acknowledgements

The Rotterdam Study is funded by the Erasmus Medical Center and the Erasmus University Rotterdam, The Netherlands Organization for Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture, and Science, the Ministry for Health, Welfare, and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The generation and management of genome-wide association studies (GWAS) genotype data for the Rotterdam Study is supported by The Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), The Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO)/Netherlands Consortium for Healthy Aging (NCHA) project nr. 050-060-810. The Erasmus Rucphen Family (ERF) Study is supported by the Center for Medical Systems Biology (CMSB) of NGI, the Internationale Stichting voor Alzheimer Onderzoek (ISAO, 04516), Hersenstichting Nederland (HSN, 150207), and the Alzheimer Association (IRRG0514359). The ophthalmic part of the Rotterdam and ERF Studies is supported by The Netherlands Organization for Health Research and Development (ZonMw) grant 2200.0035; Lijf en Leven, Krimpen a/d Lek; MD Fonds, Utrecht; Oogfonds Nederland, Utrecht; Stichting Nederlands Oogheelkundig Onderzoek, Nijmegen/Rotterdam; Swart van Essen, Rotterdam; Netherlands Organisation for Scientific Research (NWO); Bevordering van Volkskracht, Rotterdam; Blindenhulp, The Hague; Blindenpenning, Amsterdam; Stichting Winckel-Sweep, Utrecht; Landelijke Stichting voor Blinden en Slechtzienden (LSBS), Utrecht; Rotterdamse Vereniging voor Blindenbelangen, Rotterdam; OOG, The Hague; Algemene Nederlandse Vereniging ter Voorkoming van Blindheid (ANVVB), Doorn; The Rotterdam Eye Hospital Research Foundation (Stichting Wetenschappelijk Onderzoek Het Oogziekenhuis [SWOO] Prof. Dr. H. J. Flieringa, Rotterdam); Lameris Ootech BV, Nieuwegein; Topcon Europe BV, Capelle aan de IJssel, all in The Netherlands; and Heidelberg Engineering, Dossenheim, Germany. The King's College London authors acknowledge funding from the Guide Dogs for the Blind Association, Wellcome Trust, the EU MyEuropia Marie Curie Research Training Network, the European Community's FP7 (HEALTH-F2-2008-201865-GEFOS), ENGAGE (HEALTH-F4-2007-201413), FP-5 GenomEUtwin Project (QLG2-CT-2002-01254), National Institutes of Health (NIH)/National Eye Institute (NEI) grant 1RO1EY018246 (PI TLY), and genotyping by the NIH Center for Inherited Disease Research (CIDR) (PI TLY). The study also receives support from the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust partnering KCL. CJH is an NIHR Senior Research Fellow. The Australian Twin Registry is supported by an Australian National Health and Medical Research Council (NHMRC) Enabling Grant (2004-2009). We also thank the following organisations for their financial support: Clifford Craig Medical Research Trust, Ophthalmic Research Institute of Australia (ORIA), American Health Assistance Foundation (AHAF), Peggy and Leslie Cranbourne Foundation, Foundation for Children, NHMRC project grant 350415 (2005-2007), Jack Brockhoff Foundation, NEI Project Grant RO1 EY 018246-01 (2007-2010) (PI TLY). Genotyping for part of the Australian sample was funded by an NHMRC Medical Genomics Grant.Genotyping for the remainder was performed by CIDR as part of an NEI/NIH project grant. Australian sample imputation analyses were carried out on the Genetic Cluster Computer which is financially supported by The Netherlands Scientific Organization (NWO 480-05-003). DAM is a recipient of the Pfizer Australia Senior Research Fellowship. SM is supported by an Australian NHMRC Career Development Award. The Wellcome Trust Case-Control Consortium 2 project was funded by the Wellcome Trust (085475/B/08/Z and 085475/Z/08/Z), the NIHR Biomedical Research Centre at Moorfields Eye Hospital NHSFT, and UCL Institute of Ophthalmology. This project included genotyping of the Blue Mountains Eye Study, which was also supported in part by the Australian National Health and Medical Research Council (512423). We acknowledge use of the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02, and of the UK National Blood Service controls funded by the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.